Tapewire

Nasdaq · USD

TVTX

Travere Therapeutics, Inc.

Export transactions ↓
Tapewire entity
1562
SEC CIK
0001438533
Parsed reports
437

Last 12 months

Inside the activity.

0 purchase rows · 116 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202506
Jan 202605
Feb 2026017
Mar 202601
Apr 2026023
May 2026015
Jun 202602
Jul 202600
Aug 202605
Sep 2026041
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 31, 2025 Filed Nov 4, 2025 21:05 UTC Exercise / conversionCommon Stock 8,000 $16.33 $130,640.00
Disclosure

SEC source: 0001376043-25-000004 · form4-11042025_041110.xml · nonDerivative · entry 1

Coughlin Timothy · CIK 0001376043 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 31, 2025 Filed Nov 4, 2025 21:05 UTC
Heerma PeterCHIEF COMMERCIAL OFFICER
SaleCommon Stock 5,591 $35.00 $195,685.00
Disclosure

SEC source: 0001789617-25-000007 · form4-11042025_041108.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,071

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Read SEC document
October 29, 2025 Filed Oct 30, 2025 20:45 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
Exercise / conversionEmployee stock option (right to buy) · Derivative 27,128 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · derivative · entry 6

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 27,128 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
October 29, 2025 Filed Oct 30, 2025 20:45 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
SaleCommon Stock 27,128 $30.12 $817,073.66
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3 · price: The weighted average sale price for the transaction reported was $30.1192, and the range of prices were between $30.00 and $30.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
October 29, 2025 Filed Oct 30, 2025 20:45 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
Exercise / conversionCommon Stock 27,128 $15.46 $419,398.88
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 446,301

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
Exercise / conversionEmployee stock option (right to buy) · Derivative 92,872 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · derivative · entry 5

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,128

Underlying: Common Stock · 92,872 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
SaleCommon Stock 92,872 $30.38 $2,821,358.49
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $30.379, and the range of prices were between $30.00 and $30.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
Exercise / conversionCommon Stock 92,872 $15.46 $1,435,801.12
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 512,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC
Heerma PeterCHIEF COMMERCIAL OFFICER
SaleCommon Stock 2,662 $30.00 $79,860.00
Disclosure

SEC source: 0001789617-25-000006 · form4-10302025_041001.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,662

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Read SEC document
September 23, 2025 Filed Sep 24, 2025 20:05 UTC
Heerma PeterCHIEF COMMERCIAL OFFICER
GiftCommon Stock 891 $0.00 $0.00
Disclosure

SEC source: 0001789617-25-000004 · form4-09242025_040905.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 127,324

F1 · kind: This transaction represents a charitable gift of 891 shares of common stock to a donor advised fund, which was gifted pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:05 UTC
REED ELIZABETH EChief Legal Officer and GC
Exercise / conversionEmployee stock option (right to buy) · Derivative 10,000 $0.00 Strike: $19.08 $0.00
Disclosure

SEC source: 0001283303-25-000005 · form4-09242025_040903.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 10,000 shares

Expires 2027-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:05 UTC
REED ELIZABETH EChief Legal Officer and GC
SaleCommon Stock 10,000 $25.00 $250,000.00
Disclosure

SEC source: 0001283303-25-000005 · form4-09242025_040903.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,878

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:05 UTC
REED ELIZABETH EChief Legal Officer and GC
Exercise / conversionCommon Stock 10,000 $19.08 $190,800.00
Disclosure

SEC source: 0001283303-25-000005 · form4-09242025_040903.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 396 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2025.

Read SEC document
September 04, 2025 Filed Sep 5, 2025 20:05 UTC
Cline Christopher R.CHIEF FINANCIAL OFFICER
SaleCommon Stock 119 $19.71 $2,345.49
Disclosure

SEC source: 0001415889-25-023786 · form4-09052025_040901.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,083

F2 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
September 03, 2025 Filed Sep 5, 2025 20:05 UTC
Cline Christopher R.CHIEF FINANCIAL OFFICER
SaleCommon Stock 454 $18.20 $8,262.80
Disclosure

SEC source: 0001415889-25-023786 · form4-09052025_040901.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,202

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
August 27, 2025 Filed Aug 28, 2025 20:05 UTC
Cline Christopher R.CHIEF FINANCIAL OFFICER
SaleCommon Stock 470 $17.31 $8,135.70
Disclosure

SEC source: 0001415889-25-023209 · form4-08282025_040801.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,656

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in May 2025.

Read SEC document
July 01, 2025 Filed Jul 2, 2025 21:28 UTC
Inrig JulaCHIEF MEDICAL OFFICER
SaleCommon Stock 815 $14.65 $11,939.75
Disclosure

SEC source: 0001415889-25-019108 · form4-07022025_090753.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,787

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in February 2025.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
LYONS GARY ADirector
GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013499 · form4-05162025_070509.xml · derivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
LYONS GARY ADirector
GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013499 · form4-05162025_070509.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,500

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
Orwin John ADirector
GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013501 · form4-05162025_070513.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
Orwin John ADirector
GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013501 · form4-05162025_070513.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,375

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
Squarer RonDirector
GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013503 · form4-05162025_070517.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
Squarer RonDirector
GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013503 · form4-05162025_070517.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,375

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013504 · form4-05162025_070518.xml · derivative · entry 2

Williams Brinkley Ruth · CIK 0001344381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013504 · form4-05162025_070518.xml · nonDerivative · entry 1

Williams Brinkley Ruth · CIK 0001344381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,750

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
Poole SandraDirector
GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013502 · form4-05162025_070515.xml · derivative · entry 2

Poole Sandra · CIK 0001619622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC
Poole SandraDirector
GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013502 · form4-05162025_070515.xml · nonDerivative · entry 1

Poole Sandra · CIK 0001619622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013500 · form4-05162025_070511.xml · derivative · entry 2

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013500 · form4-05162025_070511.xml · nonDerivative · entry 1

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,500

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013498 · form4-05162025_070507.xml · derivative · entry 2

COUGHLIN TIMOTHY · CIK 0001376043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013498 · form4-05162025_070507.xml · nonDerivative · entry 1

COUGHLIN TIMOTHY · CIK 0001376043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,500

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013497 · form4-05162025_070505.xml · derivative · entry 2

Bruhn Suzanne Louise · CIK 0001517790 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013497 · form4-05162025_070505.xml · nonDerivative · entry 1

Bruhn Suzanne Louise · CIK 0001517790 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,750

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantStock option (right to buy) · Derivative 19,500 $0.00 Strike: $21.15 $0.00
Disclosure

SEC source: 0001415889-25-013496 · form4-05162025_070503.xml · derivative · entry 2

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

Read SEC document
May 15, 2025 Filed May 16, 2025 23:00 UTC GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-013496 · form4-05162025_070503.xml · nonDerivative · entry 1

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

Read SEC document
May 05, 2025 Filed May 6, 2025 01:54 UTC
Cline Christopher R.CHIEF FINANCIAL OFFICER
SaleCommon Stock 1,784 $21.05 $37,553.20
Disclosure

SEC source: 0001415889-25-012061 · form4-05062025_010528.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,126

F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
May 05, 2025 Filed May 6, 2025 01:53 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
SaleCommon Stock 18,924 $21.05 $398,350.20
Disclosure

SEC source: 0001415889-25-012058 · form4-05062025_010542.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Read SEC document
May 05, 2025 Filed May 6, 2025 01:53 UTC
Heerma PeterCHIEF COMMERCIAL OFFICER
SaleCommon Stock 1,771 $21.05 $37,279.55
Disclosure

SEC source: 0001415889-25-012057 · form4-05062025_010504.xml · nonDerivative · entry 2

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,215

F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
May 05, 2025 Filed May 6, 2025 01:52 UTC
ROTE WILLIAM E.Chief Research Officer
SaleCommon Stock 3,198 $21.05 $67,317.90
Disclosure

SEC source: 0001415889-25-012056 · form4-05062025_010518.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,241

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Read SEC document
May 05, 2025 Filed May 6, 2025 01:51 UTC
REED ELIZABETH EChief Legal Officer and GC
SaleCommon Stock 4,920 $21.05 $103,566.00
Disclosure

SEC source: 0001415889-25-012054 · form4-05062025_010531.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,482

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:54 UTC
Cline Christopher R.CHIEF FINANCIAL OFFICER
Exercise / conversionPerformance-based restricted stock units · Derivative 4,920 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-012061 · form4-05062025_010528.xml · derivative · entry 3

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,920

Underlying: Common Stock · 4,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Common Stock of the Issuer.

F1 · kind: On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.exercise_date: On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.expiration_date: On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:54 UTC
Cline Christopher R.CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 4,920 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-012061 · form4-05062025_010528.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F2 · price: Each PSU represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:53 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
Exercise / conversionPerformance-based restricted stock units · Derivative 18,924 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-012058 · form4-05062025_010542.xml · derivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,924

Underlying: Common Stock · 18,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:53 UTC
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
Exercise / conversionCommon Stock 18,924 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-012058 · form4-05062025_010542.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 438,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:53 UTC
Heerma PeterCHIEF COMMERCIAL OFFICER
Exercise / conversionPerformance-based restricted stock units · Derivative 4,920 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-012057 · form4-05062025_010504.xml · derivative · entry 3

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,920

Underlying: Common Stock · 4,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:53 UTC
Heerma PeterCHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 4,920 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-012057 · form4-05062025_010504.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,986

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:52 UTC
ROTE WILLIAM E.Chief Research Officer
Exercise / conversionPerformance-based restricted stock units · Derivative 4,920 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-012056 · form4-05062025_010518.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,920

Underlying: Common Stock · 4,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:52 UTC
ROTE WILLIAM E.Chief Research Officer
Exercise / conversionCommon Stock 4,920 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-012056 · form4-05062025_010518.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:51 UTC
REED ELIZABETH EChief Legal Officer and GC
Exercise / conversionPerformance-based restricted stock units · Derivative 4,920 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-012054 · form4-05062025_010531.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,920

Underlying: Common Stock · 4,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved

F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved

F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved

Read SEC document
May 02, 2025 Filed May 6, 2025 01:51 UTC
REED ELIZABETH EChief Legal Officer and GC
Exercise / conversionCommon Stock 4,920 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-012054 · form4-05062025_010531.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,402

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.